CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Don’t miss our latest news! Sign up today for our free newsletter.
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Brazil will break the patent on Abbott Laboratories' protease inhibitor Kaletra and begin making generic versions of the drug unless Abbott lowers the price of the pill by 42% within 10 days, health officials announced Friday. Brazilian health minister Humberto Costa informed Abbott that the company must lower the cost of the drug to $1.17 per pill. A generic version of the drug made by Brazilian state-run laboratory Farmanguinhos would cost only 68 cents per pill, according to Costa. The country would break the patent under national and international laws that allow generic versions of patented drugs to be made during periods of national emergencies. If the patent is broken, it would be mark the first time any government has broken one on an HIV antiretroviral drug and the first time Brazil broken a patent on any medication. Abbott says the nation does not have a legal basis to break the patent on Kaletra and says the company already sells it at the lowest price outside of Africa. "A compulsory license is not in the best interest of Brazilian patients because it puts the government's desire to cut health care spending ahead of patients' need for new and better treatments," Abbott said in a press release. The company did not say how it planned to respond to Brazil's announcement. Brazil is currently negotiating for price reductions on Merck's Sustiva and Gilead Science's Viread. The country already makes several generic versions of anti-HIV drugs, which it provides for free to its HIV-positive citizens through the nation's highly touted HIV prevention and treatment program. U.S. AIDS advocates praised the decision by Brazilian officials to break patents on anti-HIV drugs that pharmaceutical companies will not steeply discount. "The medicines are critical for HIV treatment when initial combinations of medicine have failed," said Asia Russell of Health Global Access Project. "The high cost of second generation patented HIV/AIDS drugs threatens the sustainability of treatment programs not only in Brazil but throughout the developing world. Now other countries, particularly countries with the capacity to produce and export medicines to other countries, must follow suit and break the patent monopolies of overpriced AIDS drugs in order to ensure access to affordable lifelong treatment."
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Lauren Boebert Caught Fondling Date’s Genitals During Family-Friendly Musical: Video
September 15 2023 11:20 PM
Don’t miss our latest news! Sign up today for our free newsletter.
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Latest Stories
Jann Wenner's Legacy: Janis Joplin Lamented Rolling Stone Story Days Before Death
September 19 2023 9:56 PM
Watch Matt Bomer and Jonathan Bailey Get Steamy in 'Fellow Travelers' Clip
September 19 2023 8:03 PM
Sarah McBride Leads Delaware Congressional Poll and Would Be First Trans U.S. Representative
September 19 2023 6:52 PM
Missouri Republican Vows to Burn 'Woke Pornographic Books' If Elected Governor
September 19 2023 5:00 PM
Incel Influencer Sneako’s Young Fans Yell ‘All Gays Should Die’ in Viral Video
September 19 2023 4:05 PM
Marjorie Taylor Greene Shares Fake Video of Pride Flag Tussle as If It's Real
September 19 2023 11:00 AM
Lauren Boebert Apparently Disinvited From Right-Wing Youth Conference Over Theater Scandal
September 18 2023 5:33 PM